BRAF and melanoma: From the US payer perspective, the vemurafenib-plus-cobimetinib strategy could be regarded as the most cost-effective treatment for patients with BRAF-mutant advanced melanoma when we set the WTP threshold at 150,000/QALY compared with the other 3 competing strategies.